CSL Management

Management Kriterienprüfungen 4/4

CSL's CEO ist Paul McKenzie, ernannt in Mar 2023, hat eine Amtszeit von 1.17 Jahren. Die jährliche Gesamtvergütung beträgt $4.41M, bestehend aus 29% Gehalt und 71% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.005% der Aktien des Unternehmens, im Wert von A$6.31M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.6 Jahre bzw. 4.4 Jahre.

Wichtige Informationen

Paul McKenzie

Geschäftsführender

US$4.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	29.0%
Amtszeit als Geschäftsführer	1.3yrs
Eigentum des Geschäftsführers	0.005%
Durchschnittliche Amtszeit des Managements	3.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.5yrs

Jüngste Management Updates

Recent updates

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Oct 26

We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation

Oct 05

Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

Sep 02

CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate

Jul 22

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Paul McKenzie im Vergleich zu den Einnahmen von CSL verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Vergütung im Vergleich zum Markt: PaulDie Gesamtvergütung ($USD4.41M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Australian ($USD4.18M).

Entschädigung vs. Einkommen: PaulDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Paul McKenzie (58 yo)

1.3yrs

Amtszeit

US$4,409,610

Vergütung

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul McKenzie	MD, CEO & Executive Director	1.3yrs	US$4.41m	0.0046% $ 6.6m
Joy Linton	Chief Financial Officer	3.3yrs	US$3.31m	0.0024% $ 3.4m
Mark Dehring	Head of Investor Relations	no data	keine Daten	keine Daten
Gregory Boss	Executive VP of Legal & General Counsel	15.4yrs	US$2.31m	keine Daten
Christina Hickie	Senior Manager of Communications	no data	keine Daten	keine Daten
Roanne Parry	Chief Human Resources Officer	less than a year	keine Daten	keine Daten
Karen Etchberger	Executive Vice President of Quality & Business Services	14.2yrs	US$2.14m	keine Daten
Jemimah Brennan	Head of Communications - Asia Pacific	no data	keine Daten	keine Daten
Andrew Nash	Senior Vice President of Research	no data	keine Daten	keine Daten
William Mezzanotte	Executive VP & Head of Research and Development	5.7yrs	US$2.14m	keine Daten
Mark Hill	Chief Digital Information Officer & Executive VP	3.7yrs	keine Daten	keine Daten
Deirdre BeVard	Senior Vice President of Research & Development Strategic Operations	no data	keine Daten	keine Daten

3.7yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrenes Management: CSLDas Führungsteam des Unternehmens gilt als erfahren (3.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul McKenzie	MD, CEO & Executive Director	1.5yrs	US$4.41m	0.0046% $ 6.6m
Megan Clark	Independent Non Executive Director	8.3yrs	US$242.27k	0.0011% $ 1.5m
Alison Watkins	Independent Non-Executive Director	2.8yrs	US$213.24k	0.00073% $ 1.0m
Carolyn Hewson	Independent Non-Executive Director	4.5yrs	US$234.27k	0.00043% $ 613.4k
Brian McNamee	Independent Non-Executive Chairman	6.3yrs	US$601.22k	0.026% $ 37.3m
Robert Cuthbertson	Non-Independent Non-Executive Director	5.7yrs	US$220.29k	0.015% $ 20.8m
Duncan Maskell	Independent Non-Executive Director	2.8yrs	US$187.33k	0.00028% $ 399.5k
Marie McDonald	Independent Non-Executive Director	10.8yrs	US$213.87k	0.00086% $ 1.2m
Samantha Lewis	Director	less than a year	keine Daten	0.00039% $ 556.4k

4.5yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: CSLDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).

CSL Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

Recent updates

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Chairman exercised options to buy AU$74k worth of stock.

Independent Non-Executive Director recently bought AU$54k worth of stock